Evidence map›Paper›PMID 24940599›Full record

ArticlePloS one2014

Plasma metabolomic profiling to reveal antipyretic mechanism of Shuang-huang-lian injection on yeast-induced pyrexia rats.

Xiaoyan Gao, Mingxing Guo, Qiang Li, Long Peng, Haiyu Liu, Li Zhang, Xu Bai, Yingxin Wang, Jian Li, Chengke Cai

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Antioxidants (Basel, Switzerland) · 2023
    Article
  6. Article
  7. The Use of Chinese Skullcap (Animals : an open access journal from MDPI · 2021
    Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Xiaoyan GaoScience experiment center for TCM, Beijing University of Chinese Medicine, Beijing, China.
Mingxing GuoScience experiment center for TCM, Beijing University of Chinese Medicine, Beijing, China.
Qiang LiSchool of Chinese material medica, Beijing University of Chinese Medicine, Beijing, China.
Long PengScience experiment center for TCM, Beijing University of Chinese Medicine, Beijing, China.
Haiyu LiuScience experiment center for TCM, Beijing University of Chinese Medicine, Beijing, China.
Li ZhangScience experiment center for TCM, Beijing University of Chinese Medicine, Beijing, China.
Xu BaiWaters technologies (Shanghai) Ltd., Shanghai, China.
Yingxin WangThe 2nd Traditional Chinese Medicine factory of Harbin pharm group CO. LTD, Harbin, China.
Jian LiSchool of Basic Medical Sciences, Beijing University of Chinese Medicine, Beijing, China.
Chengke CaiSchool of Chinese material medica, Beijing University of Chinese Medicine, Beijing, China.
Beijing University of Chinese Medicine · CNWaters (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Shuang-huang-lian injection (SHLI) is a famous Chinese patent medicine, which has been wildly used in clinic for the treatment of acute respiratory tract infection, pneumonia, influenza, etc. The existing randomized controlled trial (RCT) studies suggested that SHLI could afford a certain anti-febrile action. However, seldom does research concern the pharmacological mechanisms of SHLI. In the current study, we explored plasma metabolomic profiling technique and selected potential metabolic markers to reveal the antipyretic mechanism of SHLI on yeast-induced pyrexia rat model using UPLC-Q-TOF/MS coupled with multivariate statistical analysis and pattern recognition techniques. We discovered a significant perturbance of metabolic profile in the plasma of fever rats and obvious reversion in SHLI-administered rats. Eight potential biomarkers, i.e. 1) 3-hydeoxybutyric acid, 2) leucine, 3) 16:0 LPC, 4) allocholic acid, 5) vitamin B2, 6) Cys-Lys-His, 7) 18:2 LPC, and 8) 3-hydroxychola-7, 22-dien-24-oic acid, were screened out by OPLS-DA approach. Five potential perturbed metabolic pathways, i.e. 1) valine, leucine, and isoleucine biosynthesis, 2) glycerophospholipid metabolism, 3) ketone bodies synthesis and degradation, 4) bile acid biosynthesis, and 5) riboflavin metabolism, were revealed to relate to the antipyretic mechanisms of SHLI. Overall, we investigated antipyretic mechanisms of SHLI at metabolomic level for the first time, and the obtained results highlights the necessity of adopting metabolomics as a reliable tool for understanding the holism and synergism of Chinese patent drug.

Indexed as

MetabolomeAmino AcidsAnimalsAntipyreticsBiomarkersDrugs, Chinese HerbalFatty AcidsFeverMaleRatsRats, Sprague-DawleySpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationYeastsAmino AcidsAntipyreticsBiomarkersDrugs, Chinese HerbalFatty Acidsshuang-huang-lian

Identifiers

PMID24940599
PMCPMC4062457
OpenAlexW1999073504

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.